<DOC>
	<DOCNO>NCT01219075</DOCNO>
	<brief_summary>RATIONALE : Chemoprevention use certain drug keep cancer forming . The use soy isoflavones supplement may prevent treat early stage breast cancer . PURPOSE : This clinical trial study soy isoflavones supplementation treat woman high risk breast cancer .</brief_summary>
	<brief_title>Soy Isoflavones Supplementation Treating Women High Risk For With Breast Cancer</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . To assess whether magnetic resonance imaging ( MRI ) volume ( equivalent 3-dimensional mammographic density ) reduce high-risk woman invasive breast cancer DCIS supplement daily soy ( 5p mg total isoflavones aglycone ) compare placebo ( microcrystalline cellulose ) tablets 1 year.II . To assess whether cell proliferation apoptosis , measure Ki67 caspase 3 staining , respectively , breast epithelial cell alter soy treatment.SECONDARY OBJECTIVES : I . To assess whether intermediate molecular marker include estrogen receptor alpha ( ER alpha ) ER beta differ woman supplement soy v placebo . OUTLINE : Patients randomize 1 2 treatment arms.ARM I : Patients receive oral soy isoflavones supplement daily for12 month absence disease progression.ARM II : Patients receive oral placebo daily 12 month absence disease progression .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma Situ</mesh_term>
	<mesh_term>Carcinoma , Ductal , Breast</mesh_term>
	<mesh_term>Carcinoma , Intraductal , Noninfiltrating</mesh_term>
	<mesh_term>Carcinoma , Lobular</mesh_term>
	<mesh_term>Phytoestrogens</mesh_term>
	<criteria>Women high risk breast cancer , define follow group : Five year Gail risk &gt; 1.7 % Known BRCA1/BRCA2 mutation carrier Family history consistent hereditary breast cancer Prior biopsy exhibit atypical hyperplasia lobular carcinoma situ ( LCIS ) History invasive breast cancer ductal carcinoma situ ( DCIS ) complete standard therapy include tamoxifen/aromatase inhibitor treat tamoxifen/aromatase inhibitor Signed Informed Consent Metastatic breast cancer Undergoing treatment ( chemotherapy , radiation , SERMs ) Pregnancy breastfeeding , plan become pregnant within one year prior study entry Regular soy consumer ( i.e. , &lt; per week soy food , soy supplement product ) Known food allergy soy nut Not willing avoid soy foods/supplements study period Current user exogenous hormone oral contraceptive planning use exogenous hormone duration study Can stop take aspirin NSAIDs within week breast biopsy Active participant ongoing trial</criteria>
	<gender>Female</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>June 2015</verification_date>
</DOC>